texas oncology more breakthroughs. more victories
Request an Appointment

East Texas Clinical Trials

Texas Oncology cancer centers in east Texas participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the east Texas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the east Texas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in a Clinical Trial

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the east Texas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the east Texas area and talk to you doctor to determine which clinical trial is right for you.

Anal Cancer

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Tyler

Phase: III

Bladder Cancer

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I

Brain Cancer

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Brain Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Brain Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Breast Cancer

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized Double-Blind Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized Double-Blind Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized Double-Blind Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 GDC-9545+ Palbo +/- Letro HER2- BC View

Description: (BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 GDC-9545+ Palbo +/- Letro HER2- BC View

Description: (BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 GDC-9545+ Palbo +/- Letro HER2- BC View

Description: (BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Gem Carbo BC Preserve 2 View

Description: A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Gem Carbo BC Preserve 2 View

Description: A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Gem Carbo BC Preserve 2 View

Description: A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA View

Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA View

Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA View

Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA View

Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Trila Sacit Gove TNBC View

Description: A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Trila Sacit Gove TNBC View

Description: A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Trila Sacit Gove TNBC View

Description: A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Carcinoid

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Tyler

Phase: III

Cervical Cancer

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Colon Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b AMG 510 MVASI Combo KRAS CRC View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 MVASI Combo KRAS CRC View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Endometrial Cancer

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Esophageal Cancer

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Fallopian Tube Cancer

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: II

Gastric Cancer

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II/III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II

GI

Title: Phase Ib study of gevokizumab in combination with standard of care anti-cancer therapies in patients with metastatic colorectal cancer, gastroesophageal cancer and renal cell carcinoma

Indication: GI

Location: Texas Oncology-Canton

Phase: Ib

Title: Phase Ib study of gevokizumab in combination with standard of care anti-cancer therapies in patients with metastatic colorectal cancer, gastroesophageal cancer and renal cell carcinoma

Indication: GI

Location: Texas Oncology-Tyler

Phase: Ib

Head and Neck Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Hematologic

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Canton

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Canton

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: IV

Leukemia

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: PH3 Ven+G vs FCR/BR in Fit untreated CLL View

Description: A PROSPECTIVE OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PH3 Ven+G vs FCR/BR in Fit untreated CLL View

Description: A PROSPECTIVE OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: PH3 Ven+G vs FCR/BR in Fit untreated CLL View

Description: A PROSPECTIVE OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III/IV

Title: Ph1b/2 APG-115 Azacitidine r/r AML CMML MDS View

Description: A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML CMML or MDS (APG115AU101)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 APG-115 Azacitidine r/r AML CMML MDS View

Description: A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML CMML or MDS (APG115AU101)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Ascim vs PC TKI new dx Ph+ CML View

Description: A phase III multi-center open-label randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12301)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Ascim vs PC TKI new dx Ph+ CML View

Description: A phase III multi-center open-label randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12301)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Lung Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph 2 Sotorasib KRASG12C 1L St4 NSCLC View

Description: 20190288: A Phase 2 Multicenter Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment (CodeBreaK 201)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 Nap r/r NSCLC View

Description: NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Nap r/r NSCLC View

Description: NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Nap r/r NSCLC View

Description: NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Title: Ph1b AMG 510 in Combo NSCLC KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol F)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 in Combo NSCLC KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol F)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b Sotora NSCLC KRAS p.G12C Brain Met View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b Sotora NSCLC KRAS p.G12C Brain Met View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG510 + Pembro NSCLC KRAS G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG510 + Pembro NSCLC KRAS G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: PH3 Sac Gov vs Doce NSCLC View

Description: Open-label Global Multicenter Randomized Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) With Progression on or After Platinum-Based Chemotherapy and anti-PD-1/PD-L1 Immunotherapy (GS-US-577-6153)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Lymphomas

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II/III

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: LTFU T-Cells View

Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II/III

Title: LTFU T-Cells View

Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 SINE KPT-8602 r/r MDS & AML View

Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 SINE KPT-8602 r/r MDS & AML View

Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I/II

Melanoma

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Miscellaneous

Title: A Phase III Clinical Trial for Test Use and Document Creation Only

Indication: Miscellaneous

Location: Texas Oncology-Canton

Phase: III

Title: A Phase III Clinical Trial for Test Use and Document Creation Only

Indication: Miscellaneous

Location: Texas Oncology-Tyler

Phase: III

Multiple Myeloma

Title: A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Indication: Multiple Myeloma

Location: Texas Oncology-Canton

Phase: Ib/II

Title: A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Indication: Multiple Myeloma

Location: Texas Oncology-Tyler

Phase: Ib/II

Myelodysplastic Syndrome

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Vene Aza HR-MDS View

Description: A Randomized Double-Blind Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Vene Aza HR-MDS View

Description: A Randomized Double-Blind Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Vene Aza HR-MDS View

Description: A Randomized Double-Blind Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 SINE KPT-8602 r/r MDS & AML View

Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 SINE KPT-8602 r/r MDS & AML View

Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: I/II

Myelofibrosis

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: II

Myelomas

Title: Ph1 SEA-BCMA R/R MM View

Description: A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma (SGNBCMA-001)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SEA-BCMA R/R MM View

Description: A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma (SGNBCMA-001)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: III

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: II

Neuroendocrine Tumors

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Ovarian Cancer

Title: PH3 Alpe BYL719 Olap BRCA OC View

Description: EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PH3 Alpe BYL719 Olap BRCA OC View

Description: EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Title: PH3 Alpe BYL719 Olap BRCA OC View

Description: EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 XMT-1536 ST NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1b/2 XMT-1536 ST NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Pancreatic Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC View

Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC View

Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC View

Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC View

Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: II

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Peritoneal Cancer

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: II

Prostate Cancer

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Title: Ph3 Docetaxel +/- Nivo mCRPC View

Description: A Phase 3 Randomized Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer (CA209-7DX)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 BMS986218 + Niv combo Doce met CRPC View

Description: A Phase 2 Open-label Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer (CA022-009)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 BMS986218 + Niv combo Doce met CRPC View

Description: A Phase 2 Open-label Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer (CA022-009)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 BMS986218 + Niv combo Doce met CRPC View

Description: A Phase 2 Open-label Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer (CA022-009)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Rectal Cancer

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Rectal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Renal Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Sarcoma

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Sarcoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Sarcoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Sarcoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Sarcoma

Location: Texas Oncology-Tyler

Phase: I/II

Skin Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Solid Tumors

Title: A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase 1, Multi-center, Open-label, Single-arm, Dose escalation, First-in-human Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 Monotherapy in Patients with Locally Advanced/Metastatic Solid Tumours

Indication: Solid Tumors

Location: Texas Oncology-Canton

Title: A Phase 1, Multi-center, Open-label, Single-arm, Dose escalation, First-in-human Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 Monotherapy in Patients with Locally Advanced/Metastatic Solid Tumours

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 + Palboc ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 + Palboc ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Urothelial Cancer

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 Trila Avel Uro Carcinoma View

Description: A Phase 2 Randomized Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)(G1T28-209)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Trila Avel Uro Carcinoma View

Description: A Phase 2 Randomized Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)(G1T28-209)

Indication: Urothelial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Trila Avel Uro Carcinoma View

Description: A Phase 2 Randomized Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)(G1T28-209)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Trila Avel Uro Carcinoma View

Description: A Phase 2 Randomized Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)(G1T28-209)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Texas Oncology-Canton

Title: A Phase III Clinical Trial for Test Use and Document Creation Only

Indication: Miscellaneous

Location: Texas Oncology-Canton

Phase: III

Title: A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Indication: Multiple Myeloma

Location: Texas Oncology-Canton

Phase: Ib/II

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II/III

Title: Phase Ib study of gevokizumab in combination with standard of care anti-cancer therapies in patients with metastatic colorectal cancer, gastroesophageal cancer and renal cell carcinoma

Indication: GI

Location: Texas Oncology-Canton

Phase: Ib

Title: A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase 1, Multi-center, Open-label, Single-arm, Dose escalation, First-in-human Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 Monotherapy in Patients with Locally Advanced/Metastatic Solid Tumours

Indication: Solid Tumors

Location: Texas Oncology-Canton

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Brain Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized Double-Blind Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 GDC-9545+ Palbo +/- Letro HER2- BC View

Description: (BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: IV

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Gem Carbo BC Preserve 2 View

Description: A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA View

Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Trila Sacit Gove TNBC View

Description: A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Canton

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b AMG 510 MVASI Combo KRAS CRC View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: I

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: II/III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: II

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II/III

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: I

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Canton

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Canton

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: II

Title: PH3 Ven+G vs FCR/BR in Fit untreated CLL View

Description: A PROSPECTIVE OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III/IV

Title: Ph1b/2 APG-115 Azacitidine r/r AML CMML MDS View

Description: A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML CMML or MDS (APG115AU101)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph3 Ascim vs PC TKI new dx Ph+ CML View

Description: A phase III multi-center open-label randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12301)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph2 Nap r/r NSCLC View

Description: NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Title: Ph1b AMG 510 in Combo NSCLC KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol F)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b Sotora NSCLC KRAS p.G12C Brain Met View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG510 + Pembro NSCLC KRAS G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: I

Title: LTFU T-Cells View

Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II/III

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: I

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph1/2 SINE KPT-8602 r/r MDS & AML View

Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph3 Vene Aza HR-MDS View

Description: A Randomized Double-Blind Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: III

Title: Ph1/2 SINE KPT-8602 r/r MDS & AML View

Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Canton

Phase: II

Title: Ph1 SEA-BCMA R/R MM View

Description: A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma (SGNBCMA-001)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: I

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: PH3 Alpe BYL719 Olap BRCA OC View

Description: EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1b/2 XMT-1536 ST NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC View

Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: III

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph2 BMS986218 + Niv combo Doce met CRPC View

Description: A Phase 2 Open-label Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer (CA022-009)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Rectal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Sarcoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Sarcoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 + Palboc ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: IV

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph2 Trila Avel Uro Carcinoma View

Description: A Phase 2 Randomized Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)(G1T28-209)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Texas Oncology-Longview Cancer Center

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized Double-Blind Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 GDC-9545+ Palbo +/- Letro HER2- BC View

Description: (BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Gem Carbo BC Preserve 2 View

Description: A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA View

Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Trila Sacit Gove TNBC View

Description: A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH3 Ven+G vs FCR/BR in Fit untreated CLL View

Description: A PROSPECTIVE OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III/IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 Nap r/r NSCLC View

Description: NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Vene Aza HR-MDS View

Description: A Randomized Double-Blind Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH3 Alpe BYL719 Olap BRCA OC View

Description: EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC View

Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 BMS986218 + Niv combo Doce met CRPC View

Description: A Phase 2 Open-label Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer (CA022-009)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph2 Trila Avel Uro Carcinoma View

Description: A Phase 2 Randomized Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)(G1T28-209)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Texas Oncology-Palestine Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA View

Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph2 Trila Avel Uro Carcinoma View

Description: A Phase 2 Randomized Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)(G1T28-209)

Indication: Urothelial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Texas Oncology-Paris

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: III/IV

Title: Ph 2 Sotorasib KRASG12C 1L St4 NSCLC View

Description: 20190288: A Phase 2 Multicenter Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment (CodeBreaK 201)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: PH3 Sac Gov vs Doce NSCLC View

Description: Open-label Global Multicenter Randomized Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) With Progression on or After Platinum-Based Chemotherapy and anti-PD-1/PD-L1 Immunotherapy (GS-US-577-6153)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC View

Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Title: Ph3 Docetaxel +/- Nivo mCRPC View

Description: A Phase 3 Randomized Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer (CA209-7DX)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Texas Oncology-Tyler

Title: A Phase III Clinical Trial for Test Use and Document Creation Only

Indication: Miscellaneous

Location: Texas Oncology-Tyler

Phase: III

Title: A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Indication: Multiple Myeloma

Location: Texas Oncology-Tyler

Phase: Ib/II

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: Phase Ib study of gevokizumab in combination with standard of care anti-cancer therapies in patients with metastatic colorectal cancer, gastroesophageal cancer and renal cell carcinoma

Indication: GI

Location: Texas Oncology-Tyler

Phase: Ib

Title: A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase 1, Multi-center, Open-label, Single-arm, Dose escalation, First-in-human Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 Monotherapy in Patients with Locally Advanced/Metastatic Solid Tumours

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Brain Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized Double-Blind Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA View

Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 3 BYL719 + nabpax TNBC PIK3CA View

Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 GDC-9545+ Palbo +/- Letro HER2- BC View

Description: (BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Gem Carbo BC Preserve 2 View

Description: A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA View

Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Trila Sacit Gove TNBC View

Description: A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b AMG 510 MVASI Combo KRAS CRC View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: PH2/3 Tuca Trast vs Placebo HER2+ GEC View

Description: MOUNTAINEER-02: A randomized double-blind placebo-controlled active comparator Phase 2/3 study of tucatinib in combination with trastuzumab ramucirumab and paclitaxel in subjects with previously treated locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) (SGNTUC-022)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: PH3 Ven+G vs FCR/BR in Fit untreated CLL View

Description: A PROSPECTIVE OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III/IV

Title: Ph1b/2 APG-115 Azacitidine r/r AML CMML MDS View

Description: A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML CMML or MDS (APG115AU101)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Ascim vs PC TKI new dx Ph+ CML View

Description: A phase III multi-center open-label randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12301)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 Nap r/r NSCLC View

Description: NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Title: Ph1b AMG 510 in Combo NSCLC KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol F)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b Sotora NSCLC KRAS p.G12C Brain Met View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG510 + Pembro NSCLC KRAS G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: LTFU T-Cells View

Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 SINE KPT-8602 r/r MDS & AML View

Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Vene Aza HR-MDS View

Description: A Randomized Double-Blind Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 SINE KPT-8602 r/r MDS & AML View

Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 SEA-BCMA R/R MM View

Description: A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma (SGNBCMA-001)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I

Title: PH3 Dara/Len vs Len NDMM View

Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: PH3 Alpe BYL719 Olap BRCA OC View

Description: EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 XMT-1536 ST NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC View

Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: PH2 CBP501 CIS NIVO PC WBC View

Description: CBP 21-01: Multicenter randomized parallel group phase 2 study to establish the efficacy and safety of combinations of CBP501 cisplatin and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10000/mm3 at screening

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 BMS986218 + Niv combo Doce met CRPC View

Description: A Phase 2 Open-label Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer (CA022-009)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Sarcoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Sarcoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 + Palboc ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 Trila Avel Uro Carcinoma View

Description: A Phase 2 Randomized Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)(G1T28-209)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

No Phase

Title: A Phase 1, Multi-center, Open-label, Single-arm, Dose escalation, First-in-human Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 Monotherapy in Patients with Locally Advanced/Metastatic Solid Tumours

Indication: Solid Tumors

Location: Texas Oncology-Canton

Title: A Phase 1, Multi-center, Open-label, Single-arm, Dose escalation, First-in-human Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 Monotherapy in Patients with Locally Advanced/Metastatic Solid Tumours

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Title: Biomarker DNA Defect Men Prostate View

Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase I

Title: A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 MVASI Combo KRAS CRC View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 MVASI Combo KRAS CRC View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1a/1b LY3484356 Abem ER+ HER2- View

Description: EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 in Combo NSCLC KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol F)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 in Combo NSCLC KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol F)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b Sotora NSCLC KRAS p.G12C Brain Met View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b Sotora NSCLC KRAS p.G12C Brain Met View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG510 + Pembro NSCLC KRAS G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG510 + Pembro NSCLC KRAS G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SEA-BCMA R/R MM View

Description: A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma (SGNBCMA-001)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SEA-BCMA R/R MM View

Description: A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma (SGNBCMA-001)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Sarcoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Sarcoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/2 FIH BMS-986249 + Nivo Solid Tumor View

Description: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I First-in-human Open-label Dose-escalation Safety Pharmacokinetic and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 + Palboc ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1b AMG 510 + Palboc ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Phase I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Brain Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Brain Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 APG-115 Azacitidine r/r AML CMML MDS View

Description: A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML CMML or MDS (APG115AU101)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 APG-115 Azacitidine r/r AML CMML MDS View

Description: A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML CMML or MDS (APG115AU101)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 SINE KPT-8602 r/r MDS & AML View

Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 SINE KPT-8602 r/r MDS & AML View

Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 SINE KPT-8602 r/r MDS & AML View

Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 SINE KPT-8602 r/r MDS & AML View

Description: A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 NUV-422 r/r HG Gliomas & Solids View

Description: NUV-422-02: A Phase 1/2 Dose Escalation Safety Pharmacokinetics and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Rectal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Sarcoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Sarcoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Phase Ib

Title: Phase Ib study of gevokizumab in combination with standard of care anti-cancer therapies in patients with metastatic colorectal cancer, gastroesophageal cancer and renal cell carcinoma

Indication: GI

Location: Texas Oncology-Canton

Phase: Ib

Title: Phase Ib study of gevokizumab in combination with standard of care anti-cancer therapies in patients with metastatic colorectal cancer, gastroesophageal cancer and renal cell carcinoma

Indication: GI

Location: Texas Oncology-Tyler

Phase: Ib

Phase Ib/II

Title: A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Indication: Multiple Myeloma

Location: Texas Oncology-Canton

Phase: Ib/II

Title: A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Indication: Multiple Myeloma

Location: Texas Oncology-Tyler

Phase: Ib/II

Phase II

Title: PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA View

Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA View

Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA View

Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA View

Description: EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Trila Sacit Gove TNBC View

Description: A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Trila Sacit Gove TNBC View

Description: A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Trila Sacit Gove TNBC View

Description: A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Canton

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: Ph 2 Sotorasib KRASG12C 1L St4 NSCLC View

Description: 20190288: A Phase 2 Multicenter Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment (CodeBreaK 201)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Nap r/r NSCLC View

Description: NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Nap r/r NSCLC View

Description: NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Nap r/r NSCLC View

Description: NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-